DailyStocks Stock Article Search

https://seekingalpha.com/article/4762587-sarepta-therapeutics-inc-srpt-q4-2024-earnings-call-transcript?source=feed_sector_transcripts Feb 26, 2025 - 0

https://www.fool.com/earnings/call-transcripts/2025/02/26/sarepta-therapeutics-srpt-q4-2024-earnings-call-tr/?source=iedfolrf0000001 Feb 26, 2025 - SRPT earnings call for the period ending December 31, 2024. 0

https://www.fool.com/investing/2024/10/03/better-biotech-stock-wave-life-sciences-vs-sarepta/?source=iedfolrf0000001 Oct 03, 2024 - These two could become direct competitors relatively soon. 0

https://www.zacks.com/stock/news/2331674/dyne-reports-mixed-data-from-dmd-study-key-executives-step-down?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2331674 Sep 04, 2024 - DYN's shares plummet following mixed data from its ongoing DMD study. Senior executives of the company step down. 0

https://www.fool.com/earnings/call-transcripts/2024/08/08/sarepta-therapeutics-srpt-q2-2024-earnings-call-tr/?source=iedfolrf0000001 Aug 07, 2024 - SRPT earnings call for the period ending June 30, 2024. 0

https://www.zacks.com/stock/news/2318459/compared-to-estimates-sarepta-therapeutics-srpt-q2-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2318459 Aug 07, 2024 - While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2316287/what-makes-sarepta-therapeutics-srpt-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2316287 Aug 05, 2024 - Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. 0

https://www.fool.com/investing/2024/07/06/after-big-win-is-sarepta-therapeutics-stock-a-buy/?source=iedfolrf0000001 Jul 06, 2024 - One key issue remains unresolved, and it could be a significant one. 0

https://www.fool.com/investing/2024/07/04/sarepta-therapeutics-no-brainer-stock-buy-fda/?source=iedfolrf0000001 Jul 04, 2024 - The label expansion paves the way for much more revenue growth for Sarepta in the years ahead. 0

https://www.fool.com/investing/2024/07/03/1-soaring-growth-stock-to-buy-and-hold-for-10-year/?source=iedfolrf0000001 Jul 03, 2024 - Let's look beyond the biotech's performance this year. 0